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Abstract The reactive dicarbonyl metabolite methylglyoxal
(MG) is the precursor of the major quantitative advanced
glycation endproducts (AGEs) in physiological systems - argi-
nine-derived hydroimidazolones and deoxyguanosine-derived
imidazopurinones. The glyoxalase system in the cytoplasm of
cells provides the primary defence against dicarbonyl glycation
by catalysing the metabolism of MG and related reactive
dicarbonyls. Dicarbonyl stress is the abnormal accumulation
of dicarbonyl metabolites leading to increased protein and
DNA modification contributing to cell and tissue dysfunction
in ageing and disease. It is produced endogenously by increased
formation and/or decreased metabolism of dicarbonyl metabo-
lites. Dicarbonyl stress contributes to ageing, disease and activ-
ity of cytotoxic chemotherapeutic agents. It contributes to age-
ing through age-related decline in glyoxalase 1 (Glo-1) activity.
Glo-1 has a dual role in cancer as a tumour suppressor protein
prior to tumour development and mediator of multi-drug resis-
tance in cancer treatment, implicating dicarbonyl glycation of
DNA in carcinogenesis and dicarbonyl-driven cytotoxicity in
mechanism of action of anticancer drugs. Glo-1 is a driver of
cardiovascular disease, likely through dicarbonyl stress-driven
dyslipidemia and vascular cell dysfunction. Dicarbonyl stress is
also a contributing mediator of obesity and vascular complica-
tions of diabetes. There are also emerging roles in neurological
disorders. Glo-1 responds to dicarbonyl stress to enhance
cytoprotection at the transcriptional level through stress-
responsive increase of Glo-1 expression. Small molecule Glo-
1 inducers are in clinical development for improved metabolic,
vascular and renal health and Glo-1 inhibitors in preclinical
development for multidrug resistant cancer chemotherapy.
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Dicarbonyl stress and the glyoxalase system
Dicarbonyl stress is the abnormal accumulation of dicarbonyl
metabolites leading to increased modification of protein and
DNA contributing to cell and tissue dysfunction in ageing and
disease [1]. Highly reactive dicarbonyl metabolites often mediat-
ing dicarbonyl stress in physiological systems are methylglyoxal
(MG), glyoxal, 3-deoxyglucosone (3-DG) and others. The
glyoxalase system is a cytoplasm enzymatic pathway, which
metabolises the most highly reactive acyclic dicarbonyls –main-
ly MG and glyoxal. It thereby plays a major role in suppressing
dicarbonyl stress in physiological systems, keeping dicarbonyl
metabolites at low, tolerable levels. Typical concentrations of
glyoxal and MG are 50–150 nM in human plasma and 1–
4 μM in plant and mammalian cells [2–4]. When dicarbonyl
concentrations increase beyond this there is potential for protein
and cell dysfunction leading to impaired health and disease.
Examples of dicarbonyl stress are the increased MG in ageing
plants [2], increased MG-protein modification in ageing human
lens [5], increased plasma and tissue concentration of MG in
diabetes [6], and increased concentrations of MG and glyoxal
in renal failure [4]. Dicarbonyl stress is caused by an imbalance
of the formation and metabolism of dicarbonyl metabolites and
also by increased exposure to exogenous dicarbonyls – Fig. 1a.
In this review there is a particular but not exclusive focus onMG
as it is a major contributor to dicarbonyl stress in physiological
systems. Other recent reviews focussing mostly on dicarbonyl
stress in obesity and diabetes have been given elsewhere [7, 8].
Formation of methylglyoxal
In mammalian metabolism, MG is formed at relatively high
flux mainly by the trace level degradation of triosephosphates,
g l y c e r a l d e h y d e - 3 - p h o s p h a t e ( G A 3 P ) a n d
dihydroxyacetonephosphate (DHAP) - 0.05 – 0.1 % of flux.
GA3P was ca. 8-fold more reactive than DHAP in degrading
to MG but as the concentration ratio of DHAP/GA3P in cells
in situ is ca. 9 or similar [9], both of these triosephosphates are
important sources of MG formation in physiological systems
in situ [10]. MG formation is a minor fate of triosephosphates:
early studies with red blood cells suggested only 0.089 %
glucotriose (2 x glucose consumption) was converted to MG
[11] and our subsequent studies with endothelial cells and
fibroblasts suggest a similar flux. The rate of total cellular
formation of MG was estimated to be ca. 125 μmol/kg cell
mass per day [11], which for an adult human of 70 kg body
mass and 25 kg body cell mass [12] equates to a predicted
whole body rate of formation of ca. 3 mmol MG per day (or
ca. 3 mg/kg body weight/day). MG is also formed by the
oxidation of acetone catalysed by cytochrome P450 2E1 in
the catabolism of ketone bodies [13] – which is low except
where ketone bodies are increased as in diabetic ketoacidosis,
prolonged (>3 days) fasting or low calorie diet [13–15]. MG
may also be formed from the oxidation of aminoacetone by
semicarbazide amine oxidase (SSAO) in the catabolism of
threonine [16]. Recent estimates of the concentration and rates
of metabolism of aminoacetone in the presence and absence of
SSAO inhibitor suggest this pathway has a flux of ca.
0.1 mmol MG per day in human subjects [17] or ca. 3 % of
total MG formation. Vascular adhesion protein-1 is considered
the origin of SSAO activity in mammals in vivo [18]. It is
found in plasma, endothelium, adipose tissue and smooth
muscle and increases ca. 2-fold in congestive heart failure,
diabetes and inflammatory liver diseases [19], and may relat-
edly increase MG formation in these conditions. MG is also
formed by the degradation of proteins glycated by glucose and
the degradation ofmonosaccharides [20]. Under physiological
conditions with low level phosphate and chelation of trace
metal ion, the predicted flux of MG formation from glycated
protein degradation is ca. 0.2 mmol MG per day or ca. 7 % of
total MG formation. Dietary contributions to MG exposure
from food are normally relatively low: sweetened soft drink,
Fig. 1 Biochemistry of dicarbonyl stress. a Metabolism of MG by the glyoxalase system. b Formation of hydroimidazolone MG-H1 from arginine
residues. c Formation of imidazopurinone MGdG in DNA. Adduct residue is shown with guanyl base only
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330 ml – 0.1 μmol MG [21], fruit juice, 330 ml – 0.7 μmol,
bread/cakes, 100 g, 1–2 μmol and other foodstuffs [22]; that
is, combined likely <0.03 mmol MG per day or <1 % MG
exposure. MG in foodstuffs was also metabolised and/or
reacted with proteins before absorption in the gastrointestinal
tract and imposed dicarbonyl stress mainly in the gastrointes-
tinal lumen [23]. The diet may contribute markedly greater to
total exposure for other dicarbonyls where culinary heating is
a source of formation; for example, 3-DG [24]. Sources of
formation of MG and routes of metabolism are summarised
in Fig. 2.
Dicarbonyl metabolism by the glyoxalase system
Glyoxal and MG are metabolised mainly by glyoxalase 1
(Glo-1) of the glutathione-dependent glyoxalase system, with
minor metabolism by aldoketo reductases (AKRs) and alde-
hyde dehydrogenases (ADHs). As total MG-derived glycation
adducts excreted in urine of healthy human subjects was typ-
ically ca. 10 μmol per day [25, 26], it can be inferred that less
than 1 % MG formed endogenously modifies the proteins.
Most of the MG formed (>99%) is metabolised by glyoxalase
1 (Glo-1) and aldoketo reductase (AKR) isozymes, which
thereby constitute an enzymatic defence against MG
glycation. From studies of the level of expression of Glo-1
and AKRs [27, 28], it can be inferred that Glo-1 activity in
situ exceeds that of AKR activity for MGmetabolism by >30-
fold in all human tissues except the renal medulla where the
expression of AKR is extraordinarily high. Indeed, Glo-1 is a
highly efficient and high abundance enzyme; typically 0.02 %
of total protein [27] and is in the top 13 % of proteins by
abundance in human cells [29]. In principle, ADHs may also
metabolise glyoxal and MG to glyoxylate and pyruvate, re-
spectively. In examination of ADH-linked MG dehydroge-
nase activity in human cells to date we have found very low
or undetectable activity. AKRs and ADH catalyse the metab-
olism of 3-DG whereas Glo-1 does not [4, 30]. Other proteins,
Bglyoxalase III^ and DJ1, were proposed as glyoxalases but
their low catalytic efficiency and cellular content suggests this
is unlikely [31].
Basal and inducible expression of Glo-1, AKRs and ADH
are under stress-responsive control by nuclear factor erythroid
2–related factor 2 (Nrf2) through regulatory antioxidant re-
sponse elements (AREs) [32–36]. The cytoprotective function
of Nrf2 therefore involves enhancing basal and inducible ex-
pression and activities of enzymes of dicarbonyl metabolism
and thereby prevention of dicarbonyl stress [32]. Other regu-
latory elements in the mammalian GLO-1 gene are: metal
response element, insulin response element, early gene 2 fac-
tor-isoform-4, and activating enhancer binding protein-2α, as
reviewed [31]. Glo-1 expression is negatively regulated by
hypoxia-inducible factor-1α (HIF1α) in hypoxia [37] and also
by the receptor for advanced glycation endproducts (RAGE)
[31]. Hypoxia may be an important physiological driver of
dicarbonyl stress as it both increases MG formation by flux
through anaerobic glycolysis and likely decreases Glo-1 ex-
pression through activation of HIF1α.
Glo-1 expression is also increased by copy number varia-
tion (CNV) of the GLO-1 gene in human andmouse genomes.
Human GLO-1 is located in chromosome 6 at locus 6p21.2
[38] and mouse Glo-1 in chromosome 17 at locus 17 a3.3
[39]. Gene cloning and bioinformatics analysis showed that
human GLO-1 coding regions consists of 12 kb with introns
Fig. 2 Formation of
methylglyoxal, metabolism and
glycation of protein and DNA in
vivo. Tissue levels of MG and
MG-H1 adduct residues in tissues
are given for mice. PBMC DNA
AGEs are for human subjects and
flux of MG metabolised by the
glyoxalase system and urinary
excretion of MG-H1 free adduct
is for healthy adduct humans.
Data from [2, 63, 89, 122, 137]
and Masania, J, Shafie, A,
Rabbani, N and Thornalley, P.J.,
Unpublished observations
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separating six exons [40, 41]. CNV of human GLO-1 was
detected by Redon et al. with a prevalence of ca. 2 %. [42].
MurineGlo-1CNVwas found in inbred strains of mice which
included complete copies of Glo-1 and complete and partial
copies of other genes [43, 44], giving rise to a 2–4-fold in-
crease in Glo-1 expression. GLO-1 duplication appeared
linked to anxiety-like behaviour in mice but may rather be
due to a proximate genetic locus co-duplicated with Glo-1
[45].
At in situ concentrations of MG, GSH and Glo-1, the for-
mation and fragmentation of the hemithioacetal of MG and
GSH are rapid compared to the Glo-1-catalysed step [31]. A
consequence of this is that in situ activity of Glo-1 is directly
proportional to GSH concentration. So cellular GSH concen-
tration is an influential factor on in situ activity of Glo-1 and
oxidative or non-oxidative depletion of GSH leads to in-
creased glyoxal and MG [46]. The concentration of S-D-
lactoylglutathione (SLG) is also maintained at low levels.
This is likely so that lactoyl-transfer to protein thiol groups
and related inactivation of enzymes with functional cysteinyl
thiols is prevented [31]. SLG is also toxic if it leaks out of cells
and is metabolised by γ-glutamyl transferase and dipeptidase
with rearrangement to N-lactoylcysteine which is an inhibitor
of pyrimidine synthesis [47]. A mathematical model of the
glyoxalase pathway predicted very low levels of MG and
SLG in cells which fitted well with experimental observation
[31].
The likely evolutionary pressure for development of Glo-1
was to evolve an enzyme that accepts themajor solution species
of MG, the MG-GSH hemithioacetal, which is also highly ef-
ficient with kcat/KM at the diffusion limit. Glo-1 is thereby ex-
quisitely suited to its function. High reactivity of arginine and
cysteine residues in Glo-1 protein could be a problem for Glo-1
stability which would occur with relatively low microscopic
pKa. Our computations of microscopic pKa values (as previ-
ously described [48]) indicates functionally important R37,
R122 and C139 of human Glo-1 have high microscopic pKa
values (>12), which confers low reactivity towardsMG.Also in
cells with 1–4 μMMG, there is a pool of ca. 20 mM cysteinyl
thiol groups and ca. 80 mM arginine residues to which MG
may bind and only 2 μM and 4 μM of these, respectively, are
functionally important residues of Glo-1 [27]. Therefore, Glo-1
is very resistant to inactivation in situ by MG.
Biochemical consequences of dicarbonyl stress
Dicarbonyl stress produces increased in situ rates of glycation
by dicarbonyls of proteins, DNA and basic phospholipids.
Reaction with proteins is directed to arginine residues forming
dihydroxyimidazolidine and hydroimidazolone adducts. The
hydroimidazolone derived from MG, MG-H1, is one of the
most quantitatively and functionally important AGEs in
physiological systems – Fig. 1b. There are also minor lysine-
derived AGEs formed: Nε-carboxymethyl-lysine and Nε(1-
carboxyethyl)lysine formed from glyoxal and MG, respective-
ly, and others. Themajor source of CML formation, however, is
the oxidative degradation of Nε-fructosyl-lysine residues [49].
Dicarbonyl glycation is particularly insidious as it is direct-
ed to arginine – the amino acid residue with highest probabil-
ity of location in functional sites of proteins, modification
induces loss of charge of the side chain guanidino group and
functionally important arginine residues tend to be those most
reactive towards dicarbonyl glycation [50]. The extent of
glycation of proteins by dicarbonyls is low, usually 1–5 %,
but may increase in ageing and disease. Proteins modified by
glyoxal and MG in dicarbonyl stress are recognised as mis-
folded and directed to the proteasome for proteolysis. In yeast
an unfocussed gene deletion analysis showed strains deleted
for genes of ubiquitin-dependent protein degradation were
sensitive to glyoxal and MG toxicity [51]. Examples of phys-
iological dysfunction mediated by dicarbonyl glycation of ar-
ginine residues of proteins are: mitochondrial protein dysfunc-
tion and increased formation of reactive oxygen species
(ROS) [52], inflammatory protein expression (RAGE, S100
proteins and high mobility group box-1) [53], mitochondrial
pathway activated apoptosis [54] and cell detachment from
the extracellular matrix and anoikis [55].
A surprising observation was increased chaperone function
of αA-crystallin with very high modification by MG for re-
versing dithiothreitol- and heat-inducedmisfolding of proteins
[56].With lower, physiological extent of modification byMG,
however, the chaperone function of αA-crystallin was not
enhanced further [57].
Early studies of specific proteins modified by MG used
antibodies to the trace MG-derived AGE, argpyrimidine. In
endothelial cells the heat shock protein-27 (HSP27) was de-
tected as a major MGmodified protein [58]. This could not be
verified by ultrahigh resolution Orbitrap mass spectrometry
with direct examination for MG-modification in tryptic pep-
tides – even when modification of proteins was increased 10-
fold in cell lysates [59], suggesting earlier studies suffered
interference. Subsequent studies showed recombinant
HSP27 was modified by 500 μM – 5 mM MG at multiple
sites and MG-modified HSP27 was more protective than un-
modified protein against apoptotic cell death [60]. The phys-
iological significance is unclear, however, as recent studies
were unable to find evidence of MG modification of HSP27
[59] and increased MG and Glo-1 inhibitors tend to promote
rather than suppress apoptosis [61, 62].
Glyoxal and MG are important precursors of DNA adducts
in physiological systems: major adducts are imidazopurinones
GdG and MGdG – nucleotide AGEs. MGdG was the major
nucleotide AGE found physiologically – Fig. 1c. DNA con-
tent of MGdG exceeded those of the major DNA oxidative
damage adduct, 8-hydroxydeoxyguanosine. Increased
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nucleotide AGEs was associated with DNA strand breaks and
mutagenesis [63].
Physiological consequences of dicarbonyl stress
Where dicarbonyl stress occurs there is potential for increased
cell dysfunction, detachment from the extracellular matrix and
anoikis, and apoptosis. Cell dysfunction is driven by the ef-
fects of protein glycation: loss of substrate protein activity –
through inactivation and/or increased rate of proteolysis and
decreased half-life (unless compensatory increased expression
is activated), or by gaining a new and damaging function – for
example, low density lipoproteins become small, dense and
atherogenic by MG modification [64]. This affects multiple
proteins – the dicarbonyl proteome - in different cell and tissue
compartments [50]. The effects span multiple compartments
by diffusion of increased MG or other dicarbonyl in
dicarbonyl stress. MG permeates cell plasma membranes by
passive diffusion of the unhydrated form. This is rate limited
by MG dehydration, giving a half-life of ~4 min [2]. The half-
life of MG for metabolism by the glyoxalase system to D-
lactate from in situ rates of D-lactate formation in cells is ca.
10 min with free MG mostly (>95 %) reversibly bound to
protein. The rate of irreversible binding to protein in plasma
was ca. 3.6 h [65]. This implies that part of the MG formed
inside cells leaks out from the site of formation and may dif-
fuse through interstitial fluid into plasma and thereafter per-
meate back into interstitial fluid and cells of other tissues.
Also, MG formed from the degradation of glycated proteins
in the extracellular compartment may enter cells for metabo-
lism by Glo-1 and AKRs. The locus of dicarbonyl stress and
related pathogenesis linked to MG accumulation is therefore
likely particularly sensitive to local decrease of Glo-1 expres-
sion and activity. Kinetic considerations of the rate of
glycation of protein, similar to those for ROS [66], indicates
a diffusion distance of MG of ca. 2–3 cm before irreversible
reaction, suggesting that MG has relatively long range and
half-life to locate and modify sensitive sites of proteins, often
leading to protein inactivation and dysfunction.
Dicarbonyl stress in ageing and disease
Ageing
The link of dicarbonyl stress to ageing was unequivocally
established in a functional genomics study of Glo-1 in the
nematode C. elegans [52]. Ageing-related decline in renal
function was prevented in transgenic rats overexpressing
Glo-1 [67]. Intuitively we expect this is due to AGE accumu-
lation in proteins of tissues and body fluids with related pro-
tein dysfunction. MG-derived AGEs were increased in human
lens with age and this was linked to cataract formation [5, 68]
and also in skin but to markedly lower extent [68]. Decreased
Glo-1 activity was associated with age-linked impairment of
wound healing [69] and increased dicarbonyl stress is associ-
ated with several ageing-linked diseases – see below. Glo-1
activity declines with age so there is also increased stress on
cell proteolysis and compensatory gene expression to keep
AGE-modified proteins to a low tolerable level and provide
replacement unmodified proteins. Dicarbonyl stress is likely a
feature of proliferative senescence of fibroblasts in culture
where Glo-1 expression is decreased and glycolytic flux is
increased [70, 71]. It is also likely involved in senescence of
plants: dicarbonyl content of broccoli increased with age [2]
and MG-H1 was a major AGE in Arabidopsis leaves [72].
Obesity
For many years a genetic linkage of Glo-1 to body weight in
mice [73] and of GLO-1 to upper-arm circumference and
supra-iliac skinfold thickness in human subjects [74] sug-
gested a role for Glo-1 in obesity. In the mouse overeating
model of obesity, leptin mutant (ob/ob) mice, Glo-1 protein
was decreased 80 % in the liver [75]. Recent conference re-
ports described increased weight gain on high fat diet (HFD)-
fed mouse with through-life expression of GLO-1 siRNA and
Glo-1 deficiency, compared to wild-type controls [76], and
decreased weight gain in Glo-1 overexpressing transgenic
mice [77], suggesting a functional role of Glo-1 and
dicarbonyl stress in obesity. HFD-fed wild-type mice had in-
creased MG-H1 content of heart and liver, as judged by im-
munoassay [78]. Dicarbonyl stress may be a mediator of obe-
sity and insulin resistance and thereby a risk factor for devel-
opment of type 2 diabetes mellitus (T2DM) and non-alcoholic
fatty liver disease (NAFLD).
Diabetes and diabetic vascular complications
Hypotheses for the involvement of dicarbonyl stress in disease
are most advanced and critically evaluated for involvement in
the vascular complications of diabetes. Glo-1 activity is de-
creased andMG-H1 residue content of proteins is increased in
the kidney, retina and nerve of pre-clinical models of micro-
vascular complications of diabetes (nephropathy, retinopathy
and neuropathy) [79–83]. Functional genomics studies with
Glo-1 deficient mice and Glo-1 overexpressing transgenic
mice and preventive intervention such as high dose thiamine
and Benfotiamine support increasedMG as a risk factor linked
to the development of diabetic microvascular complications
[79, 84–87]. Dicarbonyl stress is also linked to diabetic car-
diovascular disease – see below. Formation of MG is in-
creased in cells with GLUT1 glucose transport incubated in
high glucose concentration [11, 88]. Decreased Glo-1 activity
synergises with increased MG formation to increase cellular
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and extracellular MG concentration. MG content of blood
samples was increased by up to 5–6 fold in patients with
diabetes [6]. Increased MG has been found in diabetic kidney
in vivo [89] and vascular endothelial cells in high glucose
concentration cultures in vitro [55] – including in mitochon-
dria [90]. In locations where it is difficult to excise tissues
without leaking of MG from cells and disrupting extracellular
fluid – such as retina and cellular and extracellular compart-
ment of peripheral nerve, evidence of dicarbonyl stress is in-
creased levels of dicarbonyl–derived AGEs [83, 91].
Increased MG concentration and protein content of MG-H1
was not found in liver, skeletal muscle and brain in experi-
mental models of type 1 diabetes [25, 83, 92]. MG-derived
AGEs were increased in plasma protein and skin collagen of
diabetic patients and were linked to risk of microvascular and
macrovascular complications [26, 93–95].
Dicarbonyl stress may also play a role in development of
T2DM through promotion of insulin resistance [77, 96] and
development of type 1 diabetes through mediation of beta-cell
toxicity [97]. Recent studies have found increased levels of
MG, glyoxal and 3-DG of subjects with impaired glucose tol-
erance and patients with T2DM in the fasting state and during
an oral glucose tolerance test challenge [98]; plasma and
glyoxal levels were ca. 3-fold higher for MG and glyoxal than
obtained using the reference assay protocol which control [2].
Chronic renal disease
Experimental models of renal failure, bilateral nephrectomy
and bilateral ureteral ligation - models of acute total loss and
partial loss of renal function, respectively, were associated
with profound dicarbonyl stress. Plasma glyoxal and MG in-
creased 5 and 15 fold within 72 h [99]. Patients with end stage
renal disease (ESRD) on hemodialysis and peritoneal dialysis
had increased plasma MG and flux of formation of
dicarbonyl-derived AGEs [4, 100]. The cause of dicarbonyl
stress is unlikely due to decreased dicarbonyl excretion as
there is little in normal health [23], although it is linked to
renal function [99]. Decreased Glo-1 expression by hypoxia
and inflammation in ESRD [101, 102], hypoxia-induced in-
creased anaerobic glycolysis [103] and decreased disposal of
triosephosphates by the reductive pentosephosphate pathway
(enzymes of which are inhibited by uremic toxins [104]) lead-
ing to increased formation of MG may produce dicarbonyl
stress in ESRD. Decreased Glo-1 activity in rare GLO-1
frameshift mutation heterozygote human subjects was associ-
ated with decreased glomerular filtration rate [67]. A patient
with ESRD and low Glo-1 activity had a high frequency of
recurrent cardiovascular disease (CVD) events [105]. Further
studies showed a high mortality rate in patients with homozy-
gous GLO-1 419CC mutation - reviewed in [106]. This sug-
gests a link of dicarbonyl stress to development of renal failure
and CVD complications of ESRD.
Cardiovascular disease
A recent pre-clinical and clinical integrative genomics study
revealed Glo-1 deficiency as a driver of CVD [107]. Chemical
inhibition of Glo-1 induced atherosclerosis in apoE deficient
mice [108]. MG-derived AGEs in plasma protein have been
found to be linked to risk of CVD in diabetes [94, 109]. High
levels of MG-H1 and CML were associated with rupture-
prone plaques in human carotid endarterectomy, accumulating
in macrophages surrounding the necrotic core. The expression
of Glo-1 was decreased in ruptured compared with stable
plaque segments [110]. However, overexpression of Glo-1 in
mice did not affect atherosclerotic lesion size and severity in
ApoE−/− mice with or without diabetes [111]. Unexpectedly
plasma MG and glyoxal concentration were not decreased in
Glo-1 transgenic mice. The reason for this is not clear but
dicarbonyls are predominately sourced from metabolism and
there was limited increase in Glo-1 activity of the liver in the
Glo-1 transgenic mice [112]. Dicarbonyl stress in plasma like-
ly contributes to CVD risk through induction of dyslipidaemia
and vascular cell dysfunction. MG modification of LDL in-
duced atherogenic transformation to small, dense LDL with
increased affinity for arterial walls through binding to heparan
sulfate proteoglycans [64]. MG modification of HDL induced
re-structuring of the HDL particles, increasing density, de-
creasing stability and plasma half-life in vivo [113].
Dicarbonyl stress also induces vascular cell dysfunction: si-
lencing of Glo-1 in human aortal endothelial cells changed
expression of >400 genes – including increased expression
of RAGE and associated ligands [53, 107].
Carcinogenesis, tumour growth and cancer chemotherapy
Dicarbonyl stress has a duality of function in cancer develop-
ment and treatment. Glo-1 is a tumour suppressor protein and
a mediator of multidrug resistance (MDR) in cancer chemo-
therapy. The tumour suppressor function of Glo-1 was re-
vealed in a genome-wide study in p53 knockout, Ras overex-
pression model of liver carcinogenesis [114]. This is consis-
tent with mutation arising from of dicarbonyl glycation of
DNA sometimes leading to carcinogenesis. There were 14
tumour suppressor genes found and currentlyGlo-1 is the only
one for which a readily available strategy for increased cancer
prevention exists – dietary Glo-1 inducers in functional foods.
The role of Glo-1 in MDR was revealed in a transcriptome-
wide subtraction technique of drug-sensitive and drug-
resistant tumour cell lines [115]. Increased Glo-1 expression
in tumours may be mediated through GLO-1 amplification
[116], and also by mutation and increased transcriptional ac-
tivity of Nrf2 through ARE-linked up-regulation of Glo-1
transcription [117]. High Glo-1 activity may be permissive
for growth with high glycolytic activity and flux of MG
518 Glycoconj J (2016) 33:513–525
formation [63]. MDR tumours are susceptible to cell perme-
able Glo-1 inhibitors [116, 118].
Other diseases
Following discovery of Glo-1 gene duplication in some strains
of mice with an anxiety phenotype [43], a link of Glo-1 to
pathologic anxiety was proposed – although the anxiety phe-
notype was linked to both increased and decreased Glo-1 ex-
pression [119, 120]. In attempts to link Glo-1 metabolically to
dysfunctional brain metabolism,MGwas found to agonise the
GABAA receptor in primary cerebellar granule neurons with a
median effective concentration EC50 of 10.5 μM and this was
proposed as mediator of sedation to explain increased GLO-1
CNV with an anxiety phenotype [121]. MG concentration in
mouse brain tissue is ca. 7-fold lower than this [122] and only
approached the EC50 value with dosing of 300 mg/kg MG
[121] – similar to doses producing acute toxicity [123].
Transgenic mice with 2-fold, 4-fold and 5-fold increased
Glo-1 expression had an anxiety phenotype with 4- and 5-
fold increased expression but not with 2-fold increased ex-
pression [121]. Some inconsistences remain, therefore, and
further investigation is required.
Dicarbonyl stress has also been linked to severe schizo-
phrenia through a rare frameshift mutation of GLO-1 [124],
synucleinopathies such as Parkinson’s disease in experimental
pre-clinical models [122] and Alzheimer’s disease through
clinical biomarker studies [125].
Dicarbonyl stress-based therapeutics
Alleviation of dicarbonyl stress by glyoxalase 1 inducers
Initial attempts to alleviate dicarbonyl stress were made
through dicarbonyl scavengers and claimed for dicarbonyl
scavenging properties of existing drugs in treatments for vas-
cular complications of diabetes. A challenge in the design of
dicarbonyl scavengers is to achieve sufficient reactivity for the
low concentration of drug achieved clinically with the 1000–
10,000 fold higher concentration of arginine residues in tissues
and body fluids. Aminoguanidine and phenacylthiazolium bro-
mide showed some promise but their toxicity and instability
prohibited further development [4, 126, 127]. Metformin and
pyridoxamine are not efficient scavengers of MG and where
associated with alleviation of dicarbonyl stress likely function
by other mechanisms [128–131]. High dose thiamine supple-
ments for prevention of T2DM and vascular complications of
diabetes may work partly by preventing the formation of MG
through increased disposal of triosephosphates in the reductive
pentosephosphate pathway [132, 133].
A better strategy is development of Glo-1 inducers through
activation and binding of Nrf2 to the GLO-1 functional ARE
[32]. This offers an alternative that is likely safe and effective.
It also addresses a key cause of dicarbonyl stress in disease –
disease-associated, tissue-specific deficiency of Glo-1.
Detection of Nrf2 activators for ARE-linked induction of
Glo-1 expression requires a specific screen with the GLO-1-
ARE motif or similar as not all Nrf2 activators induce expres-
sion of Glo-1. Nrf2 activators typically change expression of a
subset of ARE-linked genes. The basis of this subset selection
is unknown but it is likely determined by the level of
functionally-active Nrf2 achieved in the cell nucleus in re-
sponse to the Nrf2 activator, recruitment of relevant accessory
proteins – such as small maf proteins [134, 135], and absence
of activation of counter-signalling effects required to induce
the ARE-linked gene of interest. Nrf2 regulates inducible ex-
pression of ca. 890 genes [136]. The advantage of Nrf2 regu-
lated, ARE-regulated genes is that they are a battery of pro-
tective genes and so where co-regulated along with Glo-1,
they tend to add to the health beneficial response. In this re-
gard, concurrent induction of GSH synthesis for increased
cellular GSH concentration to support increased in situ activ-
ity of Glo-1 is particularly beneficial [137].
A Glo-1 inducer formulation has been optimised and eval-
uated in Phase 1 clinical trial (Clinicaltrials.org;
NCT02095873) in overweight and obese subjects for safety
and target pharmacology at a working dose. We also did
functional assessments – Phase 2 A trials for health
improvement in obesity. The Glo-1 inducer is a binary com-
bination of trans-resveratrol and hesperetin (tRES-HESP) and
was evaluated in a randomised, placebo-controlled crossover
clinical trial in 29 overweight and obese subjects. In highly
overweight subjects (BMI >27.5 kg/m2), tRES-HESP co-for-
mulation increased expression and activity of Glo-1, de-
creased plasma methylglyoxal and total body methylglyoxal-
protein glycation. It decreased fasting and postprandial plasma
Table 1 Therapeutic agents in development targeting the glyoxalase system
Therapeutic class Mechanism of action Primary target application (secondary) Stage of development Reference
Glyoxalase 1
inducer
Small molecule Nrf2 activator
targeting GLO-1-ARE
transcriptional activity
Diabetic nephropathy (other microvascular
complications of diabetes; obesity –
NAFLD; cardiovascular disease)
Clinical trial Phase 2 ready
(Phase 1 complete with safety,
dose and pharmacology established).
[137]
Glyoxalase 1
inhibitor
Substrate analogue inhibitor
diester (prodrug)
Cancer (GLO-1 overexpressing,
MDR tumours)
Pre-clinical in vivo models [62, 118, 140]
Glycoconj J (2016) 33:513–525 519
glucose, increased oral-glucose-insulin-sensitivity (OGIS) in-
dex – an assessment of insulin sensitivity, and improved arte-
rial dilatation. In all subjects, it decreased vascular inflamma-
tion marker sICAM-1. In previous clinical evaluations, tRES
and HESP individually were ineffective. tRES-HESP co-for-
mulation could be a suitable treatment for improvedmetabolic
and vascular health in overweight and obese populations. It
now available for evaluation in Phase 2 clinical trial against
disease targets.
This first-in-class Glo-1 inducer trial establishes Glo-1 tar-
get pharmacology for tRES-HESP. Whilst increased Glo-1
expression likely contributes to the observed health beneficial
effects, changes in other gene expression occurred and their
interplay may alsomediate the overall health benefit achieved.
Nevertheless it was pursuit and optimisation of induction of
Glo-1 expression that arrived at this synergistic combination
of bioactive compounds and achieved improved metabolic
and vascular health in overweight and obese subjects that is
unmatched by other therapy. The marked health improve-
ments were achieved with expression of many antioxidant-
linked genes unchanged – at least in the peripheral blood
mononuclear cells analysed.
Cell permeable Glo-1 inhibitors which increase dicarbonyl
stress may find use as anti-tumour and anti-microbial agents
for treatment of Glo-1-linked MDR tumours and microbial
infections. S-p-Bromobenzylglutathione diethyl ester was the
first cell permeable Glo-1 inhibitor developed and had median
growth inhibitory concentration GC50 values in the range 7–
20 μM for a range of cancer cell lines. Subsequent develop-
ment of the cyclopentyl ester derivative increased potency and
had anti-tumour activity in tumour-bearing mice [62, 138,
139]. A difficulty in clinical translation is identifying tumours
that are sensitive to Glo-1 inhibitors. These are likely tumours
with a relatively high flux of MG formation and high activity
of Glo-1 such that when a Glo-1 inhibitor is delivered into the
tumour, MG accumulates rapidly to toxic levels. GLO-1 am-
plification in tumours is not a reliable marker of this as it is not
always functional and does not report on flux of MG. Systems
modelling of the glyoxalase pathway is beneficial in assess-
ment of the potency of Glo-1 inducer or Glo-1 inhibitor re-
quired to achieve the desired pharmacological and therapeutic
effects [31].
Stages of development of therapeutics targeting dicarbonyl
stress are summarised in Table 1.
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